Dr Reddys Laboratories Ltd has reported consolidated financial results for the period ended December 31, 2025.

Dr Reddys Laboratories has reported total income of Rs. 8,726.8 crore during the period ended December 31, 2025 as compared to Rs. 8,358.6 crores during the period ended December 31, 2024. The company reported total income of Rs. 8,805.1 crores during the period ended September 30, 2025.

Dr Reddys Laboratories has posted net profit of Rs. 1,209.8 crore for the period ended December 31, 2025 as against net profit of Rs. 1,413.3 crore for the period ended December 31, 2024. The company posted net profit of Rs. 1,437.2 crore for the period ended September 30, 2025.

For the 9 months period ended December 31, 2025, Dr Reddys Laboratories has reported total income of Rs. 26,077.1 crore as compared to Rs. 24,047.5 crore during the 9 months period ended December 31, 2024.

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025 as against net profit of Rs. 4,060.6 crore for the 9 months period ended December 31, 2024. 

Commenting on the results, Co-Chairman & MD G V Prasad said: “Our growth in Q3FY26 was supported by continued momentum in our branded businesses, aided by favourable forex, thus offsetting the impact of lower Lenalidomide sales. We continue to focus on disciplined execution of our strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders.”

 

Dr Reddy’s has advanced its global and domestic footprint with several key developments in Q3FY26:

 

I. Strategic collaboration with Immutep for commercialization of the immunotherapy oncology drug Eftilagimod Alfa outside North America, Europe, Japan, and Greater China, with an upfront of US$20 million and potential milestones of up to US$349.5 million, plus double-digit royalties.

 

II. Launch of Hevaxin, a recombinant vaccine for Hepatitis-E prevention in India.

 

III. Integration of 85% of its acquired Consumer Healthcare business in the Nicotine Replacement Therapy segment completed.

 

IV. Regulatory approvals for Semaglutide injection in India and for denosumab biosimilar in the EU and UK, with a product launch in Germany in December 2025.

 

V. BLA filings completed for abatacept IV biosimilar and ongoing interactions with USFDA for denosumab and rituximab biosimilars, including responses to Complete Response Letters.

 

Dr Reddy’s says it continues to combine branded business growth, strategic acquisitions, and global pipeline expansion to drive long-term value in a challenging pharmaceutical landscape.